跳至主要内容
临床试验/NCT01238835
NCT01238835已完成不适用

Placement of AoRtic Balloon Expandable Transcatheter VAlves TrIaL (TransApical)

Edwards Lifesciences40 个研究点 分布在 4 个国家目标入组 220 人开始时间: 2009年9月1日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
220
试验地点
40
主要终点
Number of Deaths

研究概览

简要总结

A single arm, prospective multicenter non-randomized confirmatory clinical trial evaluating the Edwards SAPIEN XT™ transcatheter heart valve (model 9300TFX; "study valve"), the next generation Ascendra™ transapical delivery system, and crimper accessories.

详细描述

Purpose: The purpose of this trial is to evaluate the acute safety and effectiveness of the SAPIEN XT™ study valve and next generation Ascendra™ delivery components.

Follow-up Intervals: Subject data collection will include clinical information at baseline and during the index procedure. Subjects will undergo clinical follow-up at discharge, 30 days, 6 month annually for 5 years.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • EuroSCORE of ≥ 15 %
  • Severe senile degenerative aortic valve stenosis
  • Symptomatic aortic valve stenosis
  • Informed consent

排除标准

  • Logistic Euroscore > 40 %
  • Evidence of an acute myocardial infarction
  • Congenital unicuspid or congenital bicuspid valve/ non-calcified
  • Mixed aortic valve disease

结局指标

主要结局

Number of Deaths

时间窗: 30 days

Number of death at 30-days from the index procedure.

次要结局

  • Number of Participants With a Stroke(30-days)

研究者

发起方
Edwards Lifesciences
申办方类型
Industry
责任方
Sponsor

研究点 (40)

Loading locations...

相似试验